Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11931
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAzad, Arun Aen
dc.contributor.authorMaddison, Claireen
dc.contributor.authorStewart, Josephineen
dc.date.accessioned2015-05-16T01:33:54Z
dc.date.available2015-05-16T01:33:54Z
dc.date.issued2013-10-14en
dc.identifier.citationOnkologie 2013; 36(11): 674-6en
dc.identifier.govdoc24192773en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11931en
dc.description.abstractPazopanib is a multi-targeted tyrosine kinase inhibitor that has recently been approved for treatment of advanced clear cell renal cell carcinoma (RCC). There are no previous reports of pazopanib triggering radiation recall dermatitis (RRD).A 60-year-old male patient was commenced on pazopanib for metastatic RCC 2 weeks prior to receiving radiotherapy (10×30 Gy) to bone metastases at the T9 and L4 vertebrae and right mid-shaft of humerus. Although there were no immediate complications from radiotherapy, 2 weeks after finishing radiation he developed a pruritic, erythematous, maculo-papular rash localized to the T9 and right humeral radiotherapy fields. The patient was diagnosed with RRD induced by pazopanib and commenced on a course of oral prednisolone, which resulted in resolution of his rash. He has now completed 5 months of pazopanib with no recurrence of RRD.We report the first case of RRD triggered by pazopanib. With increasing use of pazopanib for advanced RCC, clinicians must be aware of the possibility that RRD can occur in patients treated with this agent following radiotherapy.en
dc.language.isoenen
dc.subject.otherCarcinoma, Renal Cell.complications.therapyen
dc.subject.otherChemotherapy, Adjuvant.adverse effectsen
dc.subject.otherCombined Modality Therapy.methodsen
dc.subject.otherHumansen
dc.subject.otherKidney Neoplasms.complications.therapyen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPyrimidines.adverse effects.therapeutic useen
dc.subject.otherRadiodermatitis.etiology.prevention & controlen
dc.subject.otherRadiotherapy, Conformal.adverse effectsen
dc.subject.otherSulfonamides.adverse effects.therapeutic useen
dc.subject.otherTreatment Outcomeen
dc.titleRadiation recall dermatitis induced by pazopanib.en
dc.typeJournal Articleen
dc.identifier.journaltitleOnkologieen
dc.identifier.affiliationJoint Austin-Ludwig Oncology Unit, Austin Health, Melbourne, Australiaen
dc.identifier.doi10.1159/000355649en
dc.description.pages674-6en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24192773en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Oct 12, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.